|
|
Article: The U.S. Food and Drug Administration Approves Actonel for Broader Use in Men With Osteoporosis.
- Article from:
- PR Newswire
- Article date:
- August 14, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
12 Million Men in U.S. at Risk for this Fragile Bone Disease
CINCINNATI and BRIDGEWATER, N.J., Aug. 14 /PRNewswire/ -- On August 11, 2006, the U.S. Food and Drug Administration (FDA) approved Actonel(R) (risedronate sodium tablets) 35 mg for treatment to increase bone mass in men with osteoporosis. FDA approval of this new indication for Actonel opens the door for more men with osteoporosis to benefit from Actonel treatment. Actonel 5 mg was approved in 2000 for use in men and women to prevent and treat certain forms of steroid-induced osteoporosis. Actonel 35 mg is also approved for the prevention and treatment of osteoporosis in postmenopausal women.
...